A new study has unveiled when chronic myeloid leukemia, a type of cancer that affects the blood and bone marrow, arises in ...

The addiction of cancer cells to causal gene fusions often results in amplification, in vivo, which can be exploited to reveal unidentified recurrent gene rearrangements. Based on this observation, we ...

Full approval of Vitrakvi was based on results from three clinical trials in patients with unresectable or metastatic NTRK ...

The FDA granted accelerated approval to the bispecific antibody zenocutuzumab (Bizengri) for NRG1 gene fusion-positive pancreatic adenocarcinoma and non-small cell lung cancer (NSCLC) on Wednesday.

A new study has unveiled when chronic myeloid leukemia, a type of cancer that affects the blood and bone marrow, arises in ...

A new study validates NRG1 gene fusions as a targetable driver of advanced NRG1 fusion-positive cancers, adding support for Bizengri (zenocutuzumab) as a promising treatment option.

The firm submitted data from a registrational study showing the drug's activity in adult and adolescent patients with NTRK fusion-positive solid tumors.

The U.S. Food and Drug Administration (FDA) has granted full approval to Vitrakvi (larotrectinib) for the treatment of adult ...